A recent study investigated the effect of the NLRP3 antagonist CP-456,773 (Jiang et al., 2017) (also called MCC950 or CRID3) on the development of NASH in dietary models (Mridha et al., 2017). This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.